FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286220281> ?p ?o ?g. }

• W4286220281 endingPage "26737" @default.
• W4286220281 startingPage "26723" @default.
• W4286220281 abstract "Alzheimer's disease is the most common progressive neurodegenerative mental disorder associated with loss of memory, decline in cognitive function, and dysfunction of language. The prominent pathogenic causes of this disease involve deposition of amyloid-β plaques, acetylcholine neurotransmitter deficiency, and accumulation of neurofibrillary tangles. There are multiple pathways that have been targeted to treat this disease. The inhibition of the intracellular cyclic AMP regulator phosphodiesterase IV causes the increase in CAMP levels that play an important role in the memory formation process. Organometallic chemistry works in a different way in treating pharmacological disorders. In the field of medicinal chemistry and pharmaceuticals, zinc-based amide carboxylates have been shown to be a preferred pharmacophore. The purpose of this research work was to investigate the potential of zinc amide carboxylates in inhibition of phosphodiesterase IV for the Alzheimer's disease management. Swiss Albino mice under controlled conditions were divided into seven groups with 10 mice each. Group I was injected with carboxymethylcellulose (CMC) at 1 mL/100 g dose, group II was injected with Streptozotocin (STZ) at 3 mg/kg dose, group III was injected with Piracetam acting as a standard drug at 200 mg/kg dosage, while groups IV-VII were injected with a zinc scaffold at the dose regimen of 10, 20, 40, and 80 mg/kg through intraperitoneal injection. All groups except group I were injected with Streptozotocin on the first day and third day of treatment at the dose of 3 mg/kg through an intracerebroventricular route to induce Alzheimer's disease. Afterward, respective treatment was continued for all groups for 23 days. In between the treatment regimen, groups were analyzed for memory and learning improvement through various behavioral tests such as open field, elevated plus maze, Morris water maze, and passive avoidance tests. At the end of the study, different biochemical markers in the brain were estimated like neurotransmitters (dopamine, serotonin and adrenaline), oxidative stress markers (superoxide dismutase, glutathione, and catalase), acetylcholinesterase (AchE), tau proteins, and amyloid-β levels. A PCR study was also performed. Results showed that the LD50 of the zinc scaffold is greater than 2000 mg/kg. Research indicated that the zinc scaffold has the potential to improve the memory impairment and learning behavior in Alzheimer's disease animal models in a dose-dependent manner. At the dose of 80 mg/kg, a maximum response was observed for the zinc scaffold. Maximum reduction in the acetylcholinesterase enzyme was observed at 80 mg/kg dose, which was further strengthened and verified by the PCR study. Oxidative stress was restored by the zinc scaffold due to the significant activation of the endogenous antioxidant enzymes. This research ended up with the conclusion that the zinc-based amide carboxylate scaffold has the potential to improve behavioral disturbances and vary the biochemical markers in the brain." @default.
• W4286220281 created "2022-07-21" @default.
• W4286220281 creator A5000950601 @default.
• W4286220281 creator A5006413680 @default.
• W4286220281 creator A5027301658 @default.
• W4286220281 creator A5030844152 @default.
• W4286220281 creator A5065944928 @default.
• W4286220281 creator A5066944968 @default.
• W4286220281 creator A5072499344 @default.
• W4286220281 creator A5074810281 @default.
• W4286220281 creator A5080863911 @default.
• W4286220281 creator A5085334707 @default.
• W4286220281 date "2022-07-19" @default.
• W4286220281 modified "2023-10-16" @default.
• W4286220281 title "Prospective Evaluation of an Amide-Based Zinc Scaffold as an Anti-Alzheimer Agent: <i>In Vitro</i>, <i>In Vivo</i>, and Computational Studies" @default.
• W4286220281 cites W1970694369 @default.
• W4286220281 cites W2012991711 @default.
• W4286220281 cites W2747321150 @default.
• W4286220281 cites W2766760889 @default.
• W4286220281 cites W2779319743 @default.
• W4286220281 cites W2792415059 @default.
• W4286220281 cites W2850382549 @default.
• W4286220281 cites W2885706121 @default.
• W4286220281 cites W2901424823 @default.
• W4286220281 cites W2901762999 @default.
• W4286220281 cites W2901949830 @default.
• W4286220281 cites W2905504149 @default.
• W4286220281 cites W2909240409 @default.
• W4286220281 cites W2913115242 @default.
• W4286220281 cites W2918096736 @default.
• W4286220281 cites W2922582677 @default.
• W4286220281 cites W2958665365 @default.
• W4286220281 cites W2966578320 @default.
• W4286220281 cites W2966672201 @default.
• W4286220281 cites W2969502335 @default.
• W4286220281 cites W2982305507 @default.
• W4286220281 cites W2982716509 @default.
• W4286220281 cites W2983500335 @default.
• W4286220281 cites W3003821296 @default.
• W4286220281 cites W3005521919 @default.
• W4286220281 cites W3008894930 @default.
• W4286220281 cites W3009177597 @default.
• W4286220281 cites W3033317366 @default.
• W4286220281 cites W3043048574 @default.
• W4286220281 cites W3046281341 @default.
• W4286220281 cites W3084812746 @default.
• W4286220281 cites W3090189200 @default.
• W4286220281 cites W3092304215 @default.
• W4286220281 cites W3097617228 @default.
• W4286220281 cites W3133727976 @default.
• W4286220281 cites W3138091048 @default.
• W4286220281 cites W3154393347 @default.
• W4286220281 cites W3159530258 @default.
• W4286220281 cites W3163032493 @default.
• W4286220281 cites W3172578915 @default.
• W4286220281 cites W3180805748 @default.
• W4286220281 cites W3197194806 @default.
• W4286220281 cites W4200469940 @default.
• W4286220281 cites W4213251494 @default.
• W4286220281 cites W4214938401 @default.
• W4286220281 cites W4220869631 @default.
• W4286220281 cites W50565577 @default.
• W4286220281 doi "https://doi.org/10.1021/acsomega.2c03058" @default.
• W4286220281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35936440" @default.
• W4286220281 hasPublicationYear "2022" @default.
• W4286220281 type Work @default.
• W4286220281 citedByCount "0" @default.
• W4286220281 crossrefType "journal-article" @default.
• W4286220281 hasAuthorship W4286220281A5000950601 @default.
• W4286220281 hasAuthorship W4286220281A5006413680 @default.
• W4286220281 hasAuthorship W4286220281A5027301658 @default.
• W4286220281 hasAuthorship W4286220281A5030844152 @default.
• W4286220281 hasAuthorship W4286220281A5065944928 @default.
• W4286220281 hasAuthorship W4286220281A5066944968 @default.
• W4286220281 hasAuthorship W4286220281A5072499344 @default.
• W4286220281 hasAuthorship W4286220281A5074810281 @default.
• W4286220281 hasAuthorship W4286220281A5080863911 @default.
• W4286220281 hasAuthorship W4286220281A5085334707 @default.
• W4286220281 hasBestOaLocation W42862202812 @default.
• W4286220281 hasConcept C134018914 @default.
• W4286220281 hasConcept C150903083 @default.
• W4286220281 hasConcept C185592680 @default.
• W4286220281 hasConcept C207001950 @default.
• W4286220281 hasConcept C2779280383 @default.
• W4286220281 hasConcept C555293320 @default.
• W4286220281 hasConcept C71924100 @default.
• W4286220281 hasConcept C86803240 @default.
• W4286220281 hasConcept C98274493 @default.
• W4286220281 hasConceptScore W4286220281C134018914 @default.
• W4286220281 hasConceptScore W4286220281C150903083 @default.
• W4286220281 hasConceptScore W4286220281C185592680 @default.
• W4286220281 hasConceptScore W4286220281C207001950 @default.
• W4286220281 hasConceptScore W4286220281C2779280383 @default.
• W4286220281 hasConceptScore W4286220281C555293320 @default.
• W4286220281 hasConceptScore W4286220281C71924100 @default.
• W4286220281 hasConceptScore W4286220281C86803240 @default.
• W4286220281 hasConceptScore W4286220281C98274493 @default.
• W4286220281 hasIssue "30" @default.

• next